Treatment of Neuroendocrine Carcinoma Cervix based on Next Generation Sequencing

Rose PG and Sierk A

Department of Obstetrics and Gynecology, East Carolina University, USA
Department of Anatomic Pathology, East Carolina University, USA

^*Correspondance to: Peter G Rose 

 PDF  Full Text Case Report | Open Access

Abstract:

Neuroendocrine carcinomas of the cervix are rare cancers occurring in 0.9% of cervical cancers. Reported on 280 neuroendocrine carcinomas of the cervix from the SEER database and demonstrated that these patients presented with more advanced FIGO stage, larger tumor size, and frequent nodal involvement than squamous or adenocarcinomas of the cervix. Their treatment less frequently involve hysterectomy, and patients more often receive adjuvant radiotherapy compared with both squamous cell carcinoma and adenocarcinoma of the cervix (p<0.05). Not surprisingly they have a significantly poorer survival than the more common squamous or adenocarcinomas of the cervix. Utilizing the Seer database. Reported a 3 year survival of 9.4% for patients with small cell carcinoma of the cervix who presented with distant disease.

Keywords:

Cite the Article:

Rose PG, Sierk A. Treatment of Neuroendocrine Carcinoma Cervix based on Next Generation Sequencing. Clin Oncol. 2019; 4: 1597.